Skip to main content
OpenTrials
Completed

NCT Number: NCT04539678

SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications

Among the etiologies of thrombosis, myeloproliferative neoplasia (MPN) is quite rare but should be investigated in case of thrombosis of atypical localization (digestive or cerebral) or in the context of recurrent idiopathic thrombosis in a young subject. Thrombosis could reveal an underlying MPN through the identification of a JAK2 V617F mutation. Rarely, MPN with thrombotic complications present with normal complete blood count(CBC). In case of a MPN with a thrombotic event but without CBC abnormality, anti-thrombotic treatment is recommended. But there is no recommendation for the indication of cytoreductive therapy and the clinician's decision is often empirical.

One of the major complications of for essential thrombocythemia (ET) or polycythemia vera (PV) is thrombosis and an age over 60 is a major risk factor. The treatment of thrombosis associated with TE or PV is based on recommendations the main therapeutic objective of which is to reduce the thrombotic risk. The combination of a cytoreducing agent and antithrombotic treatment is thus proposed in high-risk patients. The efficacy of this management is monitored by assessing CBC with the objective of normalization at <400 G/L of platelets for ET patients and <45% hematocrit in case of PV.

The absence of abnormal CBC makes it difficult to justify cytoreduction. The benefit of such a therapy in this context has not been clinically demonstrated. If a cytoreductive therapy is initiated, no biological parameters are available to assess the response to treatment.

The objective of this observational study is to evaluate the incidence of recurrence of thrombosis in patients whose thrombotic event revealed an underlying MPN with normal CBC. A comparison of groups treated or not with cytoreductive agents will be performed. Longitudinal monitoring of the patients will provide a better understanding of the nature and kinetics of hematological changes in these patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Thrombotic Patients Bone Marrow Diseases Cardiovascular Diseases Diagnosis of Myeloproliferative Neoplasia Embolism and Thrombosis Hematologic Diseases Hemic and Lymphatic Diseases Impact of Treatment With Cytoreducing Agent Myeloproliferative Disorders Thrombosis Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Nantes University Hospital

Nantes, Loire-Atlantique, 44093, France

About this study

This study is observational and multicentric.In a first part, patients will be retrospectively included. Baseline clinical and biological data obtainedat the time of MPN diagnosis of MPN with normal CBC following venous or arterial thrombosis will be recorded and follow-up data will be collected in an e-CRF. In a second part, patients will be included prospectively and diagnostic and follow-up data will be collected. Whether or not to initiate treatment with a cytoreduction treatment is left to the discretion of the clinician.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult ≥18 years old
  • Diagnosis of a deep arterial or venous thrombotic event verified by imaging (Doppler or CT scan)
  • Diagnosis of MPN with normal CBC according to WHO 2017 criteria characterized by the detection of a molecular abnormality JAK2V617F mutation (regardless of allelic load), CALR or MPL and/or a bone marrow biopsy with abnormalities in favor of MPN.
  • Normal blood cell count not suggestive of polycythemia vera (hematocrit<48% and hemoglobin<16g/dL for women; hematocrit<49% and hemoglobin<16.5g/dL for men), essential thrombocythemia (platelets<450 G/L) nor myelofibrosis (white blood cell count<11 G/L, no anemia or erythromyelemia associated with splenomegaly) at the time of the thrombotic event.

Exclusion criteria

  • Minors (<18 years of age)
  • Microcirculation disorders (erythromelalgia, headaches, paresthesia, ischemia of the extremities)
  • Superficial or deep arterial or venous thrombosis NOT verified by imaging
  • Diagnosis or history of TE, PV or myelofibrosis at time of first thrombotic event
  • Diagnosis of mixed myelodysplastic/myeloproliferative syndrome
  • Diagnosis of unclassifiable MPN with excess blasts at the onset or signs of myelodysplasia as defined by the WHO 2017 classification

Treatment and study plan

Primary outcomes

  1. Cumulative incidence of recurrence of thromboembolic events after the initial thrombosis leading to the diagnosis of MPN

    Time frame: 24 months follow-up

    The diagnosis of thromboembolic events must be confirmed by imaging

Secondary outcomes

  1. Cumulative incidence of hematological progression to essential thrombocythemia, polycythemia vera, secondary myelofibrosis or acute transformation

    Time frame: 24 months follow-up

    Hematological progression criteria will be based on the WHO classification

  2. Cumulative incidence of recurrence of thromboembolic events according to the type and duration of anticoagulant or anti-aggregant treatment

    Time frame: 24 months follow-up

    The diagnosis of thromboembolic event must be confirmed by imaging

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Collaborators

  • French Intergroup of Myeloproliferative syndromes

Registry information

Official study title

Retrospective and Prospective Multicenter Study Evaluating the Impact of Treatment With Cytoreducing Agents on the Recurrence of Thrombosis in Thrombotic Patients With a Diagnosis of Myeloproliferative Neoplasia and Normal Blood Counts - a FIM Study

Acronym: SYTHROM

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Sep 7, 2020
Registry last updated
Feb 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.